Response of Metastatic Angiosarcoma to Thalidomide: Possible Synergism With Radiation Therapy

Publication
Article
OncologyONCOLOGY Vol 14 No 11
Volume 14
Issue 11

A 67-year-old female developed metastatic angiosarcoma involving the scalp, left neck, and pulmonary nodules. Disease progression occurred while she received two cycles of doxorubicin/ifosfamide (Ifex)/mesna (Mesnex), complicated by sepsis

A 67-year-old female developed metastatic angiosarcoma involving the scalp, left neck, and pulmonary nodules. Disease progression occurred while she received two cycles of doxorubicin/ifosfamide (Ifex)/mesna (Mesnex), complicated by sepsis and pneumonia. Radiation was used to palliate tumor bulk in the neck (4,000 cGy in 16 fractions) with a minor response (< 10%) lasting 2 months. Upon disease progression in all three sites, oral thalidomide (Thalomid) was begun at 150 mg three times daily.

During a 6-week period, the neck mass had an 84% shrinkage (from 7.5 ´ 5 cm to 3 ´ 2 cm), while the scalp and pulmonary lesions remained unchanged. Toxicity was limited to somnolence, responding to dose reduction to 100 mg three times daily. After 2 months, thalidomide was stopped because of pulmonary progression with hemothorax and bronchopleural fistula. Progression also occurred in the scalp, but the size of the neck lesion remained unchanged up until the patient’s demise 3 months later from pulmonary complications.

CONCLUSION: Thalidomide may have a synergistic role for combined-modality therapy of angiosarcoma. Integration of thalidomide into a clinical trial of chemoradiotherapy would be feasible, straightforward, and merits evaluation.

Click here to read Wen-Jen Hwu's commentary on this abstract.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
2 experts in this video